Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

227
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
227
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

217
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
217
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

174
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
174
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

362
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
362
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

575
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

NPJ precision oncology·2026
Same author

Interpreting MALDI imaging data for rare types of ampullary cancer using machine learning.

NPJ systems biology and applications·2026
Same author

Label-free multiphoton microscopy and machine learning for recognition of hepatocellular carcinoma.

Scientific reports·2026
Same author

Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer.

JCI insight·2025
Same author

Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinoma.

Oncoimmunology·2025
Same author

Pathologist-like explainable AI for interpretable Gleason grading in prostate cancer.

Nature communications·2025

Related Experiment Video

Updated: Jul 26, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.4K

[Ulcerative colitis-associated carcinogenesis : An update].

Daniela E Aust1, Gustavo B Baretton2, Ulrich Sommer2

  • 1Institut für Pathologie, Universitätsklinikum Carl Gustav Carus Dresden an der TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. daniela.aust@ukdd.de.

Pathologie (Heidelberg, Germany)
|June 13, 2023
PubMed
Summary
This summary is machine-generated.

Ulcerative colitis (UC) patients face a higher risk of colorectal cancer (CRC). UC-related CRC develops via inflammation and genetic changes in the gut lining, impacting prevention and therapy strategies.

Keywords:
ChemopreventionColorectal neoplasmsImmune checkpoint inhibitorsMicrobiotaTumor genetics

More Related Videos

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

47.0K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Related Experiment Videos

Last Updated: Jul 26, 2025

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.4K
Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

47.0K
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

10.1K

Area of Science:

  • Gastroenterology and Oncology
  • Inflammatory Bowel Disease Research

Context:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • UC patients have an elevated risk of colorectal cancer (CRC).
  • CRC risk in UC correlates with disease onset, duration, extent, and complications like strictures and primary sclerosing cholangitis.

Purpose:

  • To summarize current knowledge on UC-related carcinogenesis.
  • To explore the impact of UC-related carcinogenesis on prevention and therapy.

Summary:

  • UC-related colorectal cancer (CRC) follows an inflammation-intraepithelial neoplasia-carcinoma sequence.
  • Genetic alterations in UC-related CRC initiate in the inflamed epithelium.
  • This differs from the sporadic adenoma-carcinoma sequence.

Impact:

  • Understanding UC carcinogenesis can inform novel prevention strategies.
  • Insights into UC-related carcinogenesis may lead to targeted therapeutic approaches.
  • Early detection and management of dysplasia in UC patients are crucial.